insense medical develops state of the art respiratory support technology as an alternative to mechanical ventilation by 2020 more than 600,000 patients in the u.s. will require mechanical ventilation. 5.7 million patients are admitted annually to icu's with 35% needing ventilation. cost of treatment is estimated at 64 bn$/y as mortality reaches 40%. imagine that instead of mechanical ventilation, or ecmo treatment, a small and safe apparatus is placed into a vein, replacing necessary lung functions without the devastating complications associated with mechanical ventilation. oxylink, an advanced nano vesicle technology. our revolutionary intravascular oxygenation apparatus, safely increases the level of oxygen & reduces the carbon dioxide in blood, enabling your physician to address the primary ventilatory condition.
Company profile
Ticker
IINN, IINNW
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IINN stock data
Latest filings (excl ownership)
6-K
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
17 Apr 24
6-K
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
10 Apr 24
6-K
Report of Foreign Private Issuer
9 Apr 24
6-K
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
3 Apr 24
424B5
Prospectus supplement for primary offering
1 Apr 24
6-K
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO’s Mother with Leading Fund Manager
1 Apr 24
6-K
Inspira™ Technologies Reports Full Year 2023 Financial Results
25 Mar 24
20-F
2023 FY
Annual report (foreign)
25 Mar 24
6-K
Inspira™ Announces AMAR Regulatory Submission of the INSPIRA™ ART100, to Enter the Southeast Asia and South American Markets
18 Mar 24
S-8
Registration of securities for employees
15 Mar 24
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
0.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 2 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 88.33 mm |
Total shares | 126.15 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Ieq Capital | 51.95 k | $77.92 mm |
Clear Street | 50.20 k | $11.00 k |
Lynwood Capital Management | 20.00 k | $4.40 mm |
MS Morgan Stanley | 4.00 k | $6.00 mm |
Proequities | 0.00 | $0.00 |
News
Inspira Technologies Oxy Q4 EPS $(0.27) Beats $(0.30) Estimate
25 Mar 24
Inspira Releases New Data Demonstrating Superiority Of Its Core Technology, Across Key Endpoints Of HMSS Indicator
12 Mar 24
Inspira Nears First FDA 510(K) Approval, 3 US Patents Approved, $546M in Summary Distribution Agreements
27 Feb 24
What's Going On With Inspira Technologies (IINN) Shares?
15 Feb 24
Why Sony Shares Are Trading Lower By Around 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
14 Feb 24
Press releases
Inspira™ Signs Term Sheet for Use of INSPIRA™ ART100 Device in Organ Transplant Procedures
16 Apr 24
Inspira™ and Ennocure In Vitro Study Results Show 100% Prevention of Bacterial Growth that Causes Bloodstream Infections
10 Apr 24
Inspira™ Announces Program to Pioneer the Applicable Use of the INSPIRA™ ART100 Device for an Artificial Womb
3 Apr 24
Inspira™ Announces $1.65 Million Registered Direct Offering of Ordinary Shares by Inspira CEO's Mother with Leading Fund Manager
1 Apr 24
Inspira™ Technologies Reports Full Year 2023 Financial Results
25 Mar 24